Copyright
©The Author(s) 2020.
World J Clin Oncol. Aug 24, 2020; 11(8): 510-527
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.510
Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.510
Table 1 Stereotactic body radiotherapy schemes for stage T1-T2 non-small cell lung cancer
| Prescription | BED10 | LC (yr) | Distance | |
| Thoracic wall | Mediastinum | |||
| 30-34 Gy single fraction | 149.6 Gy | 94% (3 yr) | > 2 cm | > 2 cm |
| 54 Gy (18 Gy × 3 fx) | 151.2 Gy | 94% (3 yr) | ≥ 2 cm | > 2 cm |
| 48 Gy (12 Gy × 4 fx) | 105.6 Gy | 85.4% (3 yr) | < 2 cm | NA |
| 50-60 Gy (10-12 Gy × 5 fx) | 100-132 Gy | 75%-84% (3 yr) | > 2 cm | ≤ 2 cm |
- Citation: Couñago F, Navarro-Martin A, Luna J, Rodríguez de Dios N, Rodríguez A, Casas F, García R, Gómez-Caamaño A, Contreras J, Serrano J. GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic. World J Clin Oncol 2020; 11(8): 510-527
- URL: https://www.wjgnet.com/2218-4333/full/v11/i8/510.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i8.510